A Phase I/II, Randomised, Single-blind, Placebo-controlled, Multiple-ascending-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD9550 in Overweight and Obese Participants With or Without Type 2 Diabetes Mellitus
Latest Information Update: 16 Jun 2025
At a glance
- Drugs AZD-9550 (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Adverse reactions; Pharmacokinetics
- Acronyms CONTEMPO
- Sponsors AstraZeneca
Most Recent Events
- 10 Jun 2025 Planned End Date changed from 31 Jul 2026 to 1 Oct 2026.
- 10 Jun 2025 Planned primary completion date changed from 31 Jul 2026 to 1 Oct 2026.
- 20 Apr 2025 Planned End Date changed from 19 May 2025 to 31 Jul 2026.